

Mayrim V Rios Perez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/279457/publications.pdf>

Version: 2024-02-01

10
papers

287
citations

1163117

8
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

715
citing authors

#	ARTICLE	IF	CITATIONS
1	CES2 sustains HNF4 β expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. <i>Molecular Metabolism</i> , 2022, 56, 101426.	6.5	14
2	CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. <i>JCO Precision Oncology</i> , 2020, 4, 426-436.	3.0	9
3	Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. <i>Cell Death and Differentiation</i> , 2019, 26, 382-393.	11.2	49
4	Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. <i>Laboratory Investigation</i> , 2018, 98, 947-956.	3.7	30
5	Extremity lipoblastoma in an adolescent. <i>Journal of Pediatric Surgery Case Reports</i> , 2018, 30, 11-13.	0.2	0
6	A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894.	7.0	76
7	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 662-670.	4.1	17
8	Transforming Growth Factor- β 2 Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 4934-4946.	7.0	31
9	<i>Ex Vivo</i> Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 6021-6030.	7.0	56
10	Regression of Stage IV Pancreatic Cancer to Curative Surgery and Introduction of a Novel Ex-Vivo Chemosensitivity Assay. <i>Cureus</i> , 2015, 7, e423.	0.5	5